BGM · BGM Group Ltd.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 21, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BGM
this stock
BGM Group Ltd.
|
$131.20M | -91.1% | +51.1% | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | +2.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.1%
- Net QoQ
- +167.9K sh
- Top holder
- GEODE CAPITAL MANAGEMENT,…
Performance
Raw-price comparisons begin at the captured split on Jun 21, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BGM | +25.0% | +16.1% | -67.0% | +16.1% | -91.1% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +24.5% | +13.1% | -80.5% | +13.1% | -103.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.